BridgeBio Pharma Inc vs Ferrari NV — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Ferrari NV trades at $408.27 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 4.3× BridgeBio Pharma Inc's market cap, and Ferrari NV pays a 1.04% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | RACE | |
|---|---|---|
Market Cap | $16.61B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $504.09 |
52-Week Low | $47.29 | $314.63 |
Enterprise Value | $18.16B | $73.60B |
Dividend Yield | — | 1.04% |
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Ferrari (RACE) trades at $412.26, up 1.22% on the day, near its pivot point of $412. The stock exhibits strong bullish momentum in moving averages and has beaten earnings estimates for three consecutive quarters. Revenue and net income have grown steadily, with 2025 revenue reaching $7.15B and net income $1.60B, though valuation ratios like a P/E of 38.45 are elevated. Recent news highlights robust demand, particularly for vehicle personalization, and the company raised its 2026 guidance following a strong Q2.
The outlook remains positive given strong fundamentals, bullish analyst sentiment, and raised guidance, but risks include high valuation multiples, potential economic sensitivity, and execution challenges with new models like the Luce EV. The consensus price target of $462.67 suggests ~12% upside, supported by institutional confidence.
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →